Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651
Robert I. Haddad(Georgetown University), Athanassios Argiris(The University of Texas at San Antonio Health Science Center), Bogdan Żurawski, Alexander Guminski(The University of Sydney), Jérôme Fayette(Université Claude Bernard Lyon 1), Urs Müller‐Richter(Comprehensive Cancer Center Mainfranken), Naomi Kiyota(Kobe University Hospital), Nabil F. Saba(Emory University), Miren Taberna(Institut Català d'Oncologia), Tariq Aziz Khan(Bristol-Myers Squibb (United States)), Karen Miller-Moslin(Bristol-Myers Squibb (United States)), Gustavo Girotto(Hospital de Base), Kevin J. Harrington(Royal Marsden NHS Foundation Trust), P. Koralewski(Unknown), Mustimbo Roberts(Bristol-Myers Squibb (United States)), Maura L. Gillison(The University of Texas MD Anderson Cancer Center), Milena Perez Mak, Amaury Daste(Centre Hospitalier Universitaire de Bordeaux), Robert L. Ferris(University of Pittsburgh), Joaquin Gabriel Reinoso Toledo, Wei Li(Bristol-Myers Squibb (United States)), Miguel Ángel Álvarez-Avitia(Instituto Nacional de Cancerología), Caroline Even(Institut Gustave Roussy), Andrzej Kawecki(The Maria Sklodowska-Curie National Research Institute of Oncology), Makoto Tahara(National Cancer Center Hospital East)
Cited by 159
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States
|Journal of Clinical Oncology|2011|3.6k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Incidence Trends for Human Papillomavirus–Related and –Unrelated Oral Squamous Cell Carcinomas in the United States
|Journal of Clinical Oncology|2008|1.6k